| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 5.66M | 7.03M | 0 | 0 |
| Revenue Growth % | - | 0.24% | -1% | - |
| Cost of Goods Sold | 0 | 0 | 1.71M | 2.13M |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 5.66M | 7.03M | -1.71M | -2.13M |
| Gross Margin % | 1% | 1% | - | - |
| Gross Profit Growth % | - | 0.24% | -1.24% | -0.25% |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M |
| OpEx % of Revenue | 5.66% | 5.18% | - | - |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M |
| SG&A % of Revenue | 1.09% | 1.14% | - | - |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M |
| R&D % of Revenue | 4.57% | 4.04% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | -2.13M |
| Operating Income | -26.35M | -29.38M | -62.41M | -142.6M |
| Operating Margin % | -4.66% | -4.18% | - | - |
| Operating Income Growth % | - | -0.12% | -1.12% | -1.29% |
| EBITDA | -25.76M | -28.33M | -60.7M | -140.47M |
| EBITDA Margin % | -4.55% | -4.03% | - | - |
| EBITDA Growth % | - | -0.1% | -1.14% | -1.31% |
| D&A (Non-Cash Add-back) | 586K | 1.05M | 1.71M | 2.13M |
| EBIT | -26.35M | -28.83M | -60.18M | -127.33M |
| Net Interest Income | -2K | 500K | 2.1M | 15.22M |
| Interest Income | 1K | 565K | 2.28M | 15.36M |
| Interest Expense | 3K | 65K | 187K | 142K |
| Other Income/Expense | -4K | 491K | 2.04M | 15.13M |
| Pretax Income | -26.35M | -28.89M | -60.37M | -127.48M |
| Pretax Margin % | -4.66% | -4.11% | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% |
| Net Income | -26.35M | -28.89M | -60.37M | -127.48M |
| Net Margin % | -4.66% | -4.11% | - | - |
| Net Income Growth % | - | -0.1% | -1.09% | -1.11% |
| Net Income (Continuing) | -26.35M | -28.89M | -60.37M | -127.48M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.02 | -1.12 | -0.00 | -3.33 |
| EPS Growth % | - | -0.1% | 1% | - |
| EPS (Basic) | -1.02 | -1.12 | -0.00 | -3.33 |
| Diluted Shares Outstanding | 25.8M | 25.8M | 673.62M | 38.33M |
| Basic Shares Outstanding | 25.8M | 25.8M | 673.62M | 38.33M |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 77.09M | 53.25M | 60.66M | 290.6M |
| Cash & Short-Term Investments | 76.07M | 51.32M | 57.54M | 285.98M |
| Cash Only | 76.07M | 37.73M | 34.65M | 96.62M |
| Short-Term Investments | 0 | 13.59M | 22.9M | 189.36M |
| Accounts Receivable | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 1.02M | 0 | 3.12M | 4.62M |
| Total Non-Current Assets | 8.4M | 13.67M | 14.53M | 15.92M |
| Property, Plant & Equipment | 7.81M | 12.44M | 10.61M | 10.66M |
| Fixed Asset Turnover | 0.72x | 0.56x | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 593K | 1.23M | 3.92M | 5.26M |
| Total Assets | 85.49M | 66.92M | 75.19M | 304.64M |
| Asset Turnover | 0.07x | 0.10x | - | - |
| Asset Growth % | - | -0.22% | 0.12% | 3.05% |
| Total Current Liabilities | 15.93M | 11.95M | 19.86M | 33.76M |
| Accounts Payable | 773K | 1.45M | 4.36M | 4.62M |
| Days Payables Outstanding | - | - | 931.85 | 791.26 |
| Short-Term Debt | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 0 | 0 | 0 |
| Other Current Liabilities | 1.72M | 565K | 9.77M | 4.88M |
| Current Ratio | 4.84x | 4.45x | 3.05x | 8.61x |
| Quick Ratio | 4.84x | 4.45x | 3.05x | 8.61x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 115.81M | 8.29M | 6.16M | 4.3M |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 4.74M | 8.29M | 6.16M | 4.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 110.05M | 6K | 0 | 0 |
| Total Liabilities | 131.74M | 20.25M | 26.02M | 38.06M |
| Total Debt | 5.55M | 10.56M | 9.08M | 8.24M |
| Net Debt | -70.51M | -27.17M | -25.57M | -88.38M |
| Debt / Equity | - | 0.23x | 0.18x | 0.03x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -8782.00x | -452.06x | -333.72x | -1004.25x |
| Total Equity | -46.25M | 46.68M | 49.18M | 266.59M |
| Equity Growth % | - | 2.01% | 0.05% | 4.42% |
| Book Value per Share | -1.79 | 1.81 | 0.07 | 6.95 |
| Total Shareholders' Equity | -46.25M | 46.68M | 49.18M | 266.59M |
| Common Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -46.78M | -75.68M | -136.04M | -263.52M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -26K | 4K | 105K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | -22.16M | -36.11M | -52.41M | -114.25M |
| Operating CF Margin % | -3.92% | -5.14% | - | - |
| Operating CF Growth % | - | -0.63% | -0.45% | -1.18% |
| Net Income | -26.35M | -28.89M | -60.37M | -127.48M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 850K | 1.13M | 605K | -5.12M |
| Working Capital Changes | -4.49M | -10.33M | 3.42M | 7.86M |
| Change in Receivables | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 11K | 677K | 4.08M | 736K |
| Cash from Investing | -1.29M | -14.1M | -8.79M | -160.9M |
| Capital Expenditures | -1.29M | -768K | -621K | -2.21M |
| CapEx % of Revenue | 0.23% | 0.11% | - | - |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 7.66M |
| Cash from Financing | 72.52M | 11.88M | 58.12M | 337.11M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | 30K | 175K | -1M | -3.1M |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | -23.44M | -36.88M | -53.03M | -116.45M |
| FCF Margin % | -4.14% | -5.25% | - | - |
| FCF Growth % | - | -0.57% | -0.44% | -1.2% |
| FCF per Share | -0.91 | -1.43 | -0.08 | -3.04 |
| FCF Conversion (FCF/Net Income) | 0.84x | 1.25x | 0.87x | 0.90x |
| Interest Paid | 3K | 65K | 187K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | -13660.99% | -125.95% | -80.74% |
| Return on Invested Capital (ROIC) | - | - | -217.11% | -105.99% |
| Gross Margin | 100% | 100% | - | - |
| Net Margin | -465.88% | -411.29% | - | - |
| Debt / Equity | - | 0.23x | 0.18x | 0.03x |
| Interest Coverage | -8782.00x | -452.06x | -333.72x | -1004.25x |
| FCF Conversion | 0.84x | 1.25x | 0.87x | 0.90x |
| Revenue Growth | - | 24.2% | -100% | - |
Kyverna Therapeutics, Inc. (KYTX) grew revenue by 0.0% over the past year. Growth has been modest.
Kyverna Therapeutics, Inc. (KYTX) reported a net loss of $161.0M for fiscal year 2024.
Kyverna Therapeutics, Inc. (KYTX) has a return on equity (ROE) of -80.7%. Negative ROE indicates the company is unprofitable.
Kyverna Therapeutics, Inc. (KYTX) had negative free cash flow of $158.4M in fiscal year 2024, likely due to heavy capital investments.